EpimAb Biotherapeutics which is essentially a biologics company based in Shanghai, China emphasizing on developing a portfolio of bispecific antibodies declared the appointment of Bin Peng who is MD, PhD as the company’s Chief Medical Officer.
Prior to this, Dr. Peng who was the former Global Head of Oncology Translational Medicine Shanghai CNIBR at Novartis proved to be a remarkable contributor to the worldwide Clinical development of Gleevec from Phase I to the market. He brings on board 25 years of international clinical development experience to EpimAb.
Chengbin Wu, PhD, Founder and CEO of EpimAb stated “Dr. Peng’s successful global leadership and expertise will be extremely beneficial to EpimAb’s portfolio of preclinical candidates, which have been developed within just two years using our proprietary bispecific antibody platform FIT-Ig. We are proud to have him on our team and look forward to his expertise and guidance as we move forward into the next stage of EpimAb’s development.”
Bin Peng, MD, PhD, stated, “I am delighted to join EpimAb at this transformative stage of its development. The company’s antibody platform technology is providing many new pipeline opportunities and I look forward to contributing to its future growth and continued success.”
Bin Peng, MD, PhD, was the Global Head of Oncology Translational Medicine, China at Novartis. Prior to this, he was appointed as the Senior Director of Clinical Pharmacology at GlaxoSmithKline, U.S. Dr. Peng served as a Senior Clinical Pharmacologist at Novartis in Switzerland where he was involved in the entire clinical development of Gleevec from 1998 with the Phase I study in humans till its worldwide registration in 2001. Dr. Peng received his MD degree from Sun Yet-Sen University of Medical Sciences in Guangzhou, China. He then earned a PhD in Cancer Clinical Pharmacology at the Cancer Research Unit, University of Newcastle Upon Tyne, U.K. and completed a postdoctoral fellowship at Manchester University, U.K.